Atypical primary cutaneous mucormycosis of the scalp

Risk factors for the infection are diabetes, neoplastic diseases, immunosuppression in organ transplant recipients, and neutropenia. First line treatment is amphotericin B. Posaconazole was recently approved to treat invasive mucormycosis. Currently they are a few cases ofmucormycosis in children, specially primary cutaneous form, Bonifaz and cols reported that cutaneous form accounts for 18.18% of all cases of mucormycosis in pediatric patients.4 Risk factors for the infection are diabetes, neoplastic diseases, immunosuppression in organ transplant recipients and neutropenia. First line treatment is amphotericin B. Posaconazole was recently approved to treat invasive mucormycosis.